STAA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
STAAR Surgical Co (STAA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. While the stock shows some potential for short-term gains, the overbought technical indicators, mixed analyst sentiment, and uncertainty in the China refractive market make it a less compelling investment for a patient, long-term strategy. Holding off for more clarity on financial performance and market recovery is advisable.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 83.321, signaling an overbought condition, which suggests potential for a pullback. Moving averages are converging, showing no clear trend. Key resistance levels are at R1: 19.912 and R2: 21.069, with the stock currently trading near these levels in pre-market.
The company has a strong gross margin of 82.21%, which increased by 6.34% YoY. The upcoming Q4 and fiscal year 2025 financial results announcement on March 3, 2026, could provide clarity on the company's performance and future outlook.
Analysts have lowered price targets recently, citing concerns about the China refractive market recovery. Insider and hedge fund activity is neutral, showing no strong conviction. Financial performance in Q3 2025 showed declining net income (-10.98% YoY) and EPS (-10.00% YoY), which raises concerns about profitability.
In Q3 2025, revenue increased by 6.93% YoY to $94.73M, but net income dropped by 10.98% YoY to $8.88M. EPS also declined by 10.00% YoY to 0.18. While gross margin improved to 82.21%, the drop in net income and EPS highlights profitability challenges.
Recent analyst ratings are mixed. Stifel lowered the price target to $19, citing challenges in the China refractive market. Wedbush initiated coverage with a Neutral rating and a $26 price target but noted risks in the company's China recovery. Canaccord reduced its price target to $22, reverting to standalone fundamentals after the failed Alcon deal.
